A 7-kDa Prion Protein (PrP) Fragment, an Integral Component of the PrP Region Required for Infectivity, Is the Major Amyloid Protein in Gerstmann-Sträussler-Scheinker Disease A117V
2001; Elsevier BV; Volume: 276; Issue: 8 Linguagem: Inglês
10.1074/jbc.m007062200
ISSN1083-351X
AutoresFabrizio Tagliavini, Patricia Lievens, Christine Tranchant, Jean-Marie Warter, Michel Mohr, Giorgio Giaccone, Francesco Perini, Giacomina Rossi, Mario Salmona, Pedro Piccardo, Bernardino Ghetti, Ronald C. Beavis, Orso Bugiani, Blas Frangione, Frances Prelli,
Tópico(s)Prion Diseases and Protein Misfolding
ResumoGerstmann-Sträussler-Scheinker disease (GSS) is a cerebral amyloidosis associated with mutations in the prion protein (PrP) gene (PRNP). The aim of this study was to characterize amyloid peptides purified from brain tissue of a patient with the A117V mutation who was Met/Val heterozygous at codon 129, Val129 being in coupling phase with mutant Val117. The major peptide extracted from amyloid fibrils was a ∼7-kDa PrP fragment. Sequence analysis and mass spectrometry showed that this fragment had ragged N and C termini, starting mainly at Gly88 and Gly90 and ending with Arg148, Glu152, or Asn153. Only Val was present at positions 117 and 129, indicating that the amyloid protein originated from mutant PrP molecules. In addition to the ∼7-kDa peptides, the amyloid fraction contained N- and C-terminal PrP fragments corresponding to residues 23–41, 191–205, and 217–228. Fibrillogenesis in vitro with synthetic peptides corresponding to PrP fragments extracted from brain tissue showed that peptide PrP-(85–148) readily assembled into amyloid fibrils. Peptide PrP-(191–205) also formed fibrillary structures although with different morphology, whereas peptides PrP-(23–41) and PrP-(217–228) did not. These findings suggest that the processing of mutant PrP isoforms associated with Gerstmann-Sträussler-Scheinker disease may occur extracellularly. It is conceivable that full-length PrP and/or large PrP peptides are deposited in the extracellular compartment, partially degraded by proteases and further digested by tissue endopeptidases, originating a ∼7-kDa protease-resistant core that is similar in patients with different mutations. Furthermore, the present data suggest that C-terminal fragments of PrP may participate in amyloid formation. Gerstmann-Sträussler-Scheinker disease (GSS) is a cerebral amyloidosis associated with mutations in the prion protein (PrP) gene (PRNP). The aim of this study was to characterize amyloid peptides purified from brain tissue of a patient with the A117V mutation who was Met/Val heterozygous at codon 129, Val129 being in coupling phase with mutant Val117. The major peptide extracted from amyloid fibrils was a ∼7-kDa PrP fragment. Sequence analysis and mass spectrometry showed that this fragment had ragged N and C termini, starting mainly at Gly88 and Gly90 and ending with Arg148, Glu152, or Asn153. Only Val was present at positions 117 and 129, indicating that the amyloid protein originated from mutant PrP molecules. In addition to the ∼7-kDa peptides, the amyloid fraction contained N- and C-terminal PrP fragments corresponding to residues 23–41, 191–205, and 217–228. Fibrillogenesis in vitro with synthetic peptides corresponding to PrP fragments extracted from brain tissue showed that peptide PrP-(85–148) readily assembled into amyloid fibrils. Peptide PrP-(191–205) also formed fibrillary structures although with different morphology, whereas peptides PrP-(23–41) and PrP-(217–228) did not. These findings suggest that the processing of mutant PrP isoforms associated with Gerstmann-Sträussler-Scheinker disease may occur extracellularly. It is conceivable that full-length PrP and/or large PrP peptides are deposited in the extracellular compartment, partially degraded by proteases and further digested by tissue endopeptidases, originating a ∼7-kDa protease-resistant core that is similar in patients with different mutations. Furthermore, the present data suggest that C-terminal fragments of PrP may participate in amyloid formation. Gerstmann-Sträussler-Scheinker disease prion protein prion protein gene normal cellular form of the prion protein disease-specific isoform of the prion protein protease-resistant core of PrPSc Creutzfeldt-Jakob disease proteinase K polyacrylamide gel electrophoresis high performance liquid chromatography N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine phenylthiohydantoin Gerstmann-Sträussler-Scheinker disease (GSS)1 is an adult-onset neurodegenerative disorder (1Gerstmann J. Sträussler E. Scheinker I. Z. Ges. Neurol. Psychiatr. 1936; 154: 736-762Crossref Scopus (228) Google Scholar, 2Farlow M.R. Tagliavini F. Bugiani O. Ghetti B. Handb. Clin. Neurol. 1991; 60: 619-663Google Scholar) that is inherited as an autosomal dominant trait and segregates with variant genotypes resulting from the combination of a pathogenic mutation (P102L, P105L, A117V, F198S, D202N, Q212P, and Q217R) and a common polymorphism at codon 129 (Met/Val) in the prion protein (PrP) gene (PRNP) (3Hsiao K. Baker H.F. Crow T.J. Poulter M. Owen F. Terwilliger J.D. Westaway D. Ott J. Prusiner S.B. Nature. 1989; 338: 342-345Crossref PubMed Scopus (697) Google Scholar, 4Doh-ura K. Tateishi J. Kitamoto T. Sakaki Y. Biochem. Biophys. Res. Commun. 1990; 163: 974-979Crossref Scopus (237) Google Scholar, 5Hsiao K. Cass C. Schellenberg G.D. Bird T. Devine-Gage E. Wisniewski H. Prusiner S.B. Neurology. 1991; 41: 681-684Crossref PubMed Scopus (139) Google Scholar, 6Dlouhy S.R. Hsiao K. Farlow M.R. Foroud T. Conneally P.M. Johnson P. Prusiner S.B. Hodes M.E. Ghetti B. Nat. Genet. 1992; 1: 64-67Crossref PubMed Scopus (186) Google Scholar, 7Hsiao K. Dlouhy S.R. Farlow M.R. Cass C. DaCosta M. Conneally P.M. Hodes M.E. Ghetti B. Prusiner S.B. Nat. Genet. 1992; 1: 68-71Crossref PubMed Scopus (216) Google Scholar, 8Kitamoto T. Ohta M. Doh-ura K. Hitoshi S. Terao Y. Tateishi J. Biochem. Biophys. Res. Commun. 1993; 191: 709-714Crossref PubMed Scopus (154) Google Scholar, 9Piccardo P. Dlouhy S.R. Lievens P.M.-J. Young K. Bird T.D. Nochlin D. Dickson D.W. Vinters H.V. Zimmermann T.R. Mackenzie I.R. Kish S.J. Ang L.C. De Carli C. Pocchiari M. Brown P. Gibbs Jr., C.J. Gajdusek D.C. Bugiani O. Ironside J. Tagliavini F. Ghetti B. J. Neuropathol. Exp. Neurol. 1998; 57: 979-988Crossref PubMed Scopus (185) Google Scholar). The pathological hallmarks of the disease are the accumulation of altered forms of PrP, termed PrPSc, and the deposition of PrP amyloid in the central nervous system (10Kitamoto T. Tateishi J. Tashima I. Ann. Neurol. 1986; 57: 230-236Google Scholar, 11Tateishi J. Kitamoto T. Hashiguchi H. Shii H. Ann. Neurol. 1988; 24: 35-40Crossref PubMed Scopus (46) Google Scholar, 12Ghetti B. Tagliavini F. Masters C.L. Beyreuther K. Giaccone G. Verga L. Farlow M.R. Conneally P.M. Dlouhy S.R. Azzarelli B. Bugiani O. Neurology. 1989; 39: 1453-1461Crossref PubMed Google Scholar, 13Giaccone G. Verga L. Bugiani O. Frangione B. Serban D. Prusiner S.B. Farlow M.R. Ghetti B. Tagliavini F. Proc. Natl. Acad. Sci. U. S. A. 1992; 89: 9349-9353Crossref PubMed Scopus (84) Google Scholar, 14Ghetti B. Piccardo P. Frangione B. Bugiani O. Giaccone G. Young K. Prelli F. Farlow M.R. Dlouhy S.R. Tagliavini F. Brain Pathol. 1996; 6: 127-145Crossref PubMed Scopus (172) Google Scholar, 15Bugiani O. Giaccone G. Piccardo P. Morbin M. Tagliavini F. Ghetti B. Microsc. Res. Tech. 2000; 50: 10-15Crossref PubMed Scopus (45) Google Scholar). The main physicochemical properties that distinguish PrPSc from the normal cellular isoform (PrPC) are a high content of β-sheet secondary structure, insolubility in nondenaturing detergents, and partial resistance to protease digestion (16Prusiner S.B. Science. 1991; 252: 1515-1522Crossref PubMed Scopus (1748) Google Scholar). In the presence of detergents, the protease-resistant core of PrPSc (termed PrPres) assembles into amyloid-like fibrils (16Prusiner S.B. Science. 1991; 252: 1515-1522Crossref PubMed Scopus (1748) Google Scholar). In previous studies we have determined the biochemical composition of amyloid fibrils extracted from brain tissue of patients with mutations F198S and Q217R in PRNP. The smallest amyloid subunit was found to correspond to a ∼7-kDa PrP fragment spanning residues ∼81 to ∼150 (17Tagliavini F. Prelli F. Ghiso J. Bugiani O. Serban D. Prusiner S.B. Farlow M.R. Ghetti B. Frangione B. EMBO J. 1991; 10: 513-519Crossref PubMed Scopus (170) Google Scholar, 18Tagliavini F. Prelli F. Porro M. Rossi G. Giaccone G. Farlow M.R. Dlouhy S.R. Ghetti B. Bugiani O. Frangione B. Cell. 1994; 79: 695-703Abstract Full Text PDF PubMed Scopus (137) Google Scholar). Although this fragment did not include the region with the amino acid substitution, it originated from mutant molecules, suggesting that the codon 198 and 217 mutations are a dominant factor for amyloidogenesis (18Tagliavini F. Prelli F. Porro M. Rossi G. Giaccone G. Farlow M.R. Dlouhy S.R. Ghetti B. Bugiani O. Frangione B. Cell. 1994; 79: 695-703Abstract Full Text PDF PubMed Scopus (137) Google Scholar). The allelic origin of the altered forms of PrP involved in the pathologic process has been investigated in other genetic prion diseases including GSS P102L, fatal familial insomnia, and Creutzfeldt-Jakob disease (CJD) associated with point or insertional mutations (19Kitamoto T. Yamaguchi K. Doh-ura K. Tateishi J. Neurology. 1991; 41: 306-310Crossref PubMed Google Scholar, 20Barbanti P. Fabbrini G. Salvatore M. Petraroli R. Cardone F. Maras B. Equestre M. Macchi G. Lenzi G.L. Pocchiari M. Neurology. 1996; 47: 734-741Crossref PubMed Scopus (69) Google Scholar, 21Chen S.G. Parchi P. Brown P. Capellari S. Zou W. Cochran E.J. Vnencak-Jones C.L. Julien J. Vital C. Mikol J. Lugaresi E. Autilio-Gambetti L. Gambetti P. Nat. Med. 1997; 3: 1009-1015Crossref PubMed Scopus (87) Google Scholar, 22Silvestrini M.C. Cardone F. Maras B. Pucci P. Barra D. Brunori M. Pocchiari M. Nat. Med. 1997; 3: 521-525Crossref PubMed Scopus (60) Google Scholar, 23Gabizon R. Telling G. Meiner Z. Halimi M. Kahana I. Prusiner S.B. Nat. Med. 1996; 2: 59-64Crossref PubMed Scopus (88) Google Scholar). These studies showed that only mutant PrP is detergent-insoluble and protease-resistant in GSS P102L (19Kitamoto T. Yamaguchi K. Doh-ura K. Tateishi J. Neurology. 1991; 41: 306-310Crossref PubMed Google Scholar, 20Barbanti P. Fabbrini G. Salvatore M. Petraroli R. Cardone F. Maras B. Equestre M. Macchi G. Lenzi G.L. Pocchiari M. Neurology. 1996; 47: 734-741Crossref PubMed Scopus (69) Google Scholar), fatal familial insomnia, and CJD D178N (21Chen S.G. Parchi P. Brown P. Capellari S. Zou W. Cochran E.J. Vnencak-Jones C.L. Julien J. Vital C. Mikol J. Lugaresi E. Autilio-Gambetti L. Gambetti P. Nat. Med. 1997; 3: 1009-1015Crossref PubMed Scopus (87) Google Scholar), whereas both the mutant and wild-type proteins have these properties in CJD V210I (22Silvestrini M.C. Cardone F. Maras B. Pucci P. Barra D. Brunori M. Pocchiari M. Nat. Med. 1997; 3: 521-525Crossref PubMed Scopus (60) Google Scholar) and CJD with five or six extra copies of the octapeptide repeat (21Chen S.G. Parchi P. Brown P. Capellari S. Zou W. Cochran E.J. Vnencak-Jones C.L. Julien J. Vital C. Mikol J. Lugaresi E. Autilio-Gambetti L. Gambetti P. Nat. Med. 1997; 3: 1009-1015Crossref PubMed Scopus (87) Google Scholar). CJD E200K illustrates an intermediate state, as the wild-type PrP is insoluble but protease-sensitive (23Gabizon R. Telling G. Meiner Z. Halimi M. Kahana I. Prusiner S.B. Nat. Med. 1996; 2: 59-64Crossref PubMed Scopus (88) Google Scholar). Thus, the recruitment of the wild-type protein into the disease process may reflect the effects of conformational changes due to specific mutations, which allow interaction between mutant and normal PrP. The present study was undertaken to characterize the amyloid protein and establish its allelic origin in a patient with GSS A117V from a previously reported Alsatian family (24Tateishi J. Kitamoto T. Doh-ura K. Sakaki Y. Steinmetz G. Tranchant C. Warter J.M. Heldt N. Neurology. 1990; 40: 1578-1581Crossref PubMed Google Scholar, 25Tranchant C. Doh-ura K. Steinmetz G. Chevalier Y. Kitamoto T. Tateishi J. Warter J.M. Rev. Neurol. (Paris). 1991; 147: 274-278PubMed Google Scholar). Specimens of cerebral cortex were fixed in 4% formaldehyde and embedded in paraplast. Seven μm thick serial sections were stained with hematoxylin-eosin, Congo Red, and thioflavine S or were immunostained with antibodies to the N terminus, mid-region, and C terminus of human PrP. These included a rabbit antiserum to a synthetic peptide homologous to residues 23–40 (PrP-(23–40)) (18Tagliavini F. Prelli F. Porro M. Rossi G. Giaccone G. Farlow M.R. Dlouhy S.R. Ghetti B. Bugiani O. Frangione B. Cell. 1994; 79: 695-703Abstract Full Text PDF PubMed Scopus (137) Google Scholar), the monoclonal antibody 3F4 which recognizes the epitope 109–112 (26Kascsak R.J. Rubenstein R. Merz P.A. Tonna-DeMasi M. Fersko R. Carp R.I. Wisniewski H.M. Diringer H. J. Virol. 1987; 61: 3688-3693Crossref PubMed Google Scholar, 27Rogers M. Serban D. Gyuris T. Scott M. Torchia T. Prusiner S.B. J. Immunol. 1991; 147: 3568-3574PubMed Google Scholar), and a monoclonal antibody to a synthetic peptide spanning residues 214–231 (SP214) (28Jimenez-Huete A. Lievens P.M.-J. Vidal R. Piccardo P. Ghetti B. Tagliavini F. Frangione B. Prelli F. Am. J. Pathol. 1998; 153: 1561-1572Abstract Full Text Full Text PDF PubMed Scopus (156) Google Scholar). The antibodies were used at a dilution of 1:200. Before immunostaining, the sections were treated with 98% formic acid for 60 min. The immunoreactions were revealed using the EnVision Plus-horseradish peroxidase system for rabbit or mouse immunoglobulins (Dako, Carpenteria, CA) and diaminobenzidine as chromogen (29Giaccone G. Canciani B. Puoti G. Rossi G. Goffredo D. Iussich S. Fociani P. Tagliavini F. Bugiani O. Brain Pathol. 2000; 10: 31-37Crossref PubMed Scopus (53) Google Scholar). Specimens of cerebral cortex and basal ganglia were homogenized in 9 volumes of lysis buffer (10 mm Tris-HCl, pH 7.5, 100 mmNaCl, 10 mm EDTA, 0.5% Nonidet P-40, 0.5% sodium deoxycholate), sonicated for 1 min, and centrifuged at 16,000 ×g at 4 °C for 15 min. To test the protease resistance of PrP, aliquots of supernatant corresponding to 100 or 250 μg of protein were digested with proteinase K (PK) at concentrations ranging from 5 to 50 μg/ml at 37 °C for 1 h. The digestion was carried out either in lysis buffer or in Laemmli's sample buffer containing 2% SDS. After PK digestion, aliquots were deglycosylated using recombinant peptide N-glycosidase F (New England Biolabs Inc., Beverly, MA) at 37 °C for 12 h, following the manufacturer's instructions. The samples were fractionated by 12.5 or 16.5% Tricine/SDS-polyacrylamide gel electrophoresis (Tricine/SDS-PAGE) under reducing conditions, transferred to polyvinylidene difluoride membranes (Millipore Corp., Bedford, MA), and probed with antibodies PrP23-40 (1:1000), 3F4 (1:50,000), and SP214 (1:200). To test the solubility of PrP in nondenaturing detergents, samples of cerebral cortex were homogenized in 9 volumes of 20 mm Tris, pH 7.5, 0.32 mm sucrose, 5 mm EDTA, and centrifuged at 1000 × g for 10 min. The resulting supernatant was further centrifuged at 100,000 × g at 4 °C for 1 h. The pellet containing cell membranes was resuspended in lysis buffer, sonicated for 1 min, and centrifuged at 100,000 × g at 4 °C for 1 h to obtain detergent-soluble and detergent-insoluble fractions. Soluble and insoluble fractions were analyzed by Western blot using the antibody 3F4. Amyloid plaque cores were isolated from 30 g of cerebral cortex. After removal of leptomeninges and large vessels, the tissue was homogenized with a Brinkmann homogenizer in buffer A (10 mm Tris-HCl, pH 7.5, 150 mm NaCl, 2 mm EDTA, 2 mm EGTA, 0.4 mm phenylmethylsulfonyl fluoride, 1% Triton X-100) at a sample to buffer ratio of 1:5 (w/v). The homogenate was sieved through 1-mm nylon mesh, and the filtrate was centrifuged at 10,000 × g for 20 min. The pellet was rehomogenized in buffer B (as for buffer A, with NaCl replaced by 0.6 m KI and the concentration of Triton X-100 reduced to 0.5%) and centrifuged at 10,000 × g for 20 min. The pellet was rehomogenized in buffer C (as for buffer B, with KI replaced by 1.5 mKCl) and centrifuged at 10,000 × g for 20 min. The pellet was washed three times in 50 mm Tris-HCl, pH 7.5, 150 mm NaCl, and centrifuged at 70,000 × gfor 30 min. The pellet was resuspended in 50 mm Tris-HCl, pH 7.5, 10 mm CaCl2, 3 mmNaN3 at a sample to buffer ratio of 1:25 (w/v), and subjected to collagenase digestion (Collagenase 3.4.24.3 type 1, Sigma) at 37 °C for 18 h, using a 1:100 (w/w) ratio of enzyme to pellet. After centrifugation at 70,000 × g for 60 min, the pellet was resuspended and washed three times in 50 mmTris-HCl, pH 7.5, loaded on a discontinuous sucrose gradient (1.0, 1.2, 1.4, 1.7, and 2.0 m sucrose in 10 mm Tris-HCl, pH 7.5), and centrifuged at 100,000 × g for 180 min. Each interface was collected, washed, and pelleted three times in 50 mm Tris-HCl, pH 7.5. Aliquots of each pellet were assessed for presence of amyloid fibrils by polarized light microscopy after Congo Red staining, fluorescence microscopy after thioflavine S treatment, and electron microscopy after negative staining with 2% aqueous phosphotungstic acid. Amyloid plaque cores were recovered in the 1.7 m sucrose fraction. The amyloid-enriched pellet was suspended in 99% formic acid and sonicated four times for 20 s. After addition of 2 volumes of distilled water, the sample was centrifuged at 10,000 × g for 10 min, and the supernatant was applied to a calibrated Sephadex G-100 column (1.2 × 120 cm) equilibrated with 3 m formic acid. Protein peaks were pooled and concentrated with a speed vacuum concentrator. The purity and molecular weight of the fractions were determined by 12.5% Tricine/SDS-PAGE under reducing conditions and by immunoblot analysis with the 3F4 antibody. The amyloid fraction was further analyzed with rabbit antisera to synthetic peptides homologous to residues 58–71, 90–102, 127–147, and 151–165 of human PrP (1:1000 dilution) as described previously (18Tagliavini F. Prelli F. Porro M. Rossi G. Giaccone G. Farlow M.R. Dlouhy S.R. Ghetti B. Bugiani O. Frangione B. Cell. 1994; 79: 695-703Abstract Full Text PDF PubMed Scopus (137) Google Scholar). Gel filtration fraction 5 that contained the major amyloid subunit was further purified by high performance liquid chromatography (HPLC) on a reverse-phase C4 column (214TP104, Vydac) with a 0–80% linear gradient of acetonitrile containing 0.1% (v/v) trifluoroacetic acid, pH 2.5. The column eluents were monitored at 214 nm, and protein peaks were lyophilized. Following Tricine/SDS-PAGE and immunoblot analysis, aliquots of the HPLC-purified, PrP-immunoreactive peptides were dissolved in 25 mm Tris-HCl, pH 8.5, 1 mm EDTA, and incubated at 37 °C for 24 h with endoproteinase Lys-C (Roche Molecular Biochemicals) at an enzyme to substrate ratio of 1:30 (w/w). The peptides generated from enzymatic digests were separated by HPLC on a reverse-phase Delta-Pak C18 column (0.39 × 30 cm, Waters, Milford, MA) with a 0–70% linear gradient of acetonitrile containing 0.1% (v/v) trifluoroacetic acid, pH 2.5. Sequence analyses of the intact amyloid protein and peptides generated by enzymatic digestion were carried out on a 477A microsequencer, and the resulting phenylthiohydantoin amino acid derivatives were identified using the on-line 120A PTH analyzer and the standard program (PE Biosystems, Foster City, CA). N- and C-terminal fragments of the amyloid protein generated by endoproteinase Lys-C digestion were reduced, repurified by HPLC on a reverse-phase C4 column, and prepared for matrix-assisted laser desorption/ionization mass spectrometry using the dried droplet method (30Hillenkamp F. Karas M. Beavis R.C. Chait B.T. Anal. Chem. 1991; 63: 1193-1203Crossref PubMed Google Scholar). The matrix used was α-cyano-4-hydroxycinnamic acid (Sigma), which was purified by recrystallization. To produce the dried droplets, a saturated solution of matrix was prepared in 2:1 aqueous 0.1% trifluoroacetic acid:acetonitrile at room temperature. The sample was added to this solution so that the final sample concentration was 1–10 mm. One-half microliter of the solution was placed on the probe of the mass spectrometer and allowed to dry. The sample was then ready for analysis. The mass spectrometer was a custom-built linear time-of-flight mass spectrometer with a 1-m flight tube with a wire ion guide operated at −50 V DC. The ion source operated at +40 kV ion acceleration potential. The laser used was an LSI-337ND (Laser Science, Boston, MA) nitrogen laser (2 ns pulse width), which was focused onto a 200-μm diameter fiber optic, conducted down 1 m of fiber optic, and then imaged onto the matrix deposit with a doublet of positive lens (magnification = 1). The detector of the mass spectrometer was a combination of a microchannel plate (the input stage) and a discrete dynode electron multiplier (amplification stage). The custom data system uses a Lecroy 9350M oscilloscope configured for dynamic range enhancement to improve the fidelity of small signals. Peptides homologous to residues 23–41, 85–148, 191–205, and 217–228 of human PrP were synthesized by solid-phase chemistry and purified by reverse-phase HPLC as described previously (31Tagliavini F. Prelli F. Verga L. Giaccone G. Sarma R. Gorevic P. Ghetti B. Passerini F. Ghibaudi E. Forloni G. Salmona M. Bugiani O. Frangione B. Proc. Natl. Acad. Sci. U. S. A. 1993; 90: 9678-9682Crossref PubMed Scopus (235) Google Scholar). Purity was greater than 95%. The peptides were suspended in deionized water or in 20 mm Tris, pH 7.0, at a concentration of 1, 5, and 10 mg/ml. Following incubation at 37 °C for 1 h or at 20 °C for 1, 3, and 7 days, 50 μl of each sample were air-dried on gelatin-coated slides, stained with 1% aqueous thioflavine S, and analyzed by fluorescence microscopy. For electron microscopy, 5 μl of suspension were applied to Formvar-coated nickel grids, negatively stained with 5% (w/v) uranyl acetate, and observed in an electron microscope model 410 (Philips Electronic Instruments, Mahwah, NJ) at 80 kV. The patient selected for this study was a 24-year-old man, whose clinico-pathologic and genetic profile has been reported in detail previously (24Tateishi J. Kitamoto T. Doh-ura K. Sakaki Y. Steinmetz G. Tranchant C. Warter J.M. Heldt N. Neurology. 1990; 40: 1578-1581Crossref PubMed Google Scholar, 25Tranchant C. Doh-ura K. Steinmetz G. Chevalier Y. Kitamoto T. Tateishi J. Warter J.M. Rev. Neurol. (Paris). 1991; 147: 274-278PubMed Google Scholar). He started at age 20 with a pseudobulbar syndrome, followed by cerebellar, extrapyramidal, and pyramidal signs, and cognitive deterioration. Neuropathologic examination revealed massive deposition of PrP-immunoreactive deposits in the cerebral cortex, thalamus, basal ganglia, and cerebellum. Most PrP deposits exhibited the tinctorial and optical properties of amyloid, i.e.birefringence after Congo Red staining and fluorescence following thioflavine S treatment. Genetically, the patient carried the silent A to G transition at the third position of PRNP codon 117 and a C to T transition at the second position of that codon, resulting in Ala → Val substitution. Furthermore, he was heterozygous Met/Val at codon 129, Val129 being in coupling phase with mutant Val117 (24Tateishi J. Kitamoto T. Doh-ura K. Sakaki Y. Steinmetz G. Tranchant C. Warter J.M. Heldt N. Neurology. 1990; 40: 1578-1581Crossref PubMed Google Scholar). To define the PrP species involved in the pathologic process, immunohistochemical and biochemical studies were undertaken. The immunohistochemical analysis of formalin-fixed, paraplast-embedded brain sections showed that the amyloid cores were immunoreactive with antibodies to the central region of the molecule, whereas antibodies to the N and C termini immunostained only the periphery of the cores (Fig.1). Western blot analysis of homogenates of cerebral cortex and basal ganglia revealed the presence of a PK-resistant PrP fragment of ∼7 kDa (Fig.2 A). This fragment was immunoreactive with antibodies to the central region while unreactive with antibodies to N- and C-terminal domains, and its electrophoretic mobility was unmodified by N-deglycosylation. The protease resistance of the 7-kDa peptide was observed under standard conditions (50 μg/ml PK in lysis buffer, 37 °C, 1 h) and was abolished by the addition of 2% SDS to the reaction buffer (data not shown). A similar 7-kDa fragment was present in brain homogenates before PK digestion, as a prominent component of a complex PrP pattern composed of ∼35-, ∼33-, and ∼28-kDa full-length PrP (i.e. di-, mono-, and nonglycosylated species), 21–22-kDa N-terminal-truncated peptides, and 16–17-kDa N- and C-terminal truncated fragments (Fig.2 A). As previously observed in the Indiana kindred of GSS with F198S mutation (32Piccardo P. Seiler C. Dlouhy S.R. Young K. Farlow M.R. Prelli F. Frangione B. Bugiani O. Tagliavini F. Ghetti B. J. Neuropathol. Exp. Neurol. 1996; 55: 1157-1163Crossref PubMed Scopus (50) Google Scholar), the relative abundance of the low molecular weight fragment was not dependent upon the extent of amyloid burden. The analysis of detergent solubility showed that ∼40% of full-length PrP partitioned in the insoluble fraction, whereas the 21–22-kDa N-terminal truncated peptides were mostly soluble, and the N- and C-terminal truncated fragments of 16–17 and 7 kDa were entirely insoluble (Fig. 2 B). Digestion of the insoluble fraction with PK verified that only the 7-kDa peptide was protease-resistant (data not shown).Figure 2Western blot analysis of PrP peptides in brain tissue homogenates and amyloid fraction, and HPLC purification of amyloid peptides. A, extract of cerebral cortex of the A117V patient before (lane 1) and after (lane 2) PK digestion or PK digestion followed by deglycosylation (lane 3). The sample has been fractionated on 16.5% Tricine-polyacrylamide minigel and probed with the antibody 3F4.B, total homogenate (lane 1), detergent-soluble (lane 2), and detergent-insoluble (lane 3) fractions, separated on 12.5% Tricine-polyacrylamide minigel and probed with the antibody 3F4. C, Western blot analysis of the amyloid protein fraction obtained from gel filtration chromatography, using antisera to synthetic peptides PrP-(58–71) (lane 1), -90–102 (lane 2), -109–112 (lane 3), -127–147 (lane 4), and -151–165 (lane 5). The major amyloid protein component migrated as a broad band centered at ∼7 kDa. This band was immunoreactive with antibodies spanning PrP residues 90–147 (lanes 2–4) and unreactive with antisera to residues 58–71 and 151–165 (lanes 1 and 5). Each lane contained 10 μg of proteins. Molecular mass markers expressed in kilodaltons are shown to theleft. D, HPLC purification of fraction 5 obtained from gel filtration chromatography. One major (peak 1) and several minor protein peaks were present in the chromatogram. Immunoblot analysis showed that peak 1 was immunoreactive with antibodies to PrP. Aliquots of this peak were used for sequence analysis and enzymatic digestion with endoproteinase Lys-C.View Large Image Figure ViewerDownload Hi-res image Download (PPT) Amyloid cores were isolated from cerebral cortex by a procedure combining buffer extraction, sieving, collagenase digestion, and sucrose gradient fractionation. As shown by light and electron microscopic analysis, amyloid cores were the main component of the final preparations; minor contaminants included lipofuscin granules and small microvessel fragments. Proteins were extracted from amyloid plaque cores with formic acid and fractionated on a Sephadex G-100 column. Gel filtration yielded two major peaks, the void volume (fraction 1) and a low molecular weight peak (fraction 5) that was present as a broad band centered at ∼7 kDa on Tricine/SDS-PAGE minigels. In addition, minor intermediary peaks (fractions 2–4) were observed in the chromatograms (data not shown). Immunoblot analysis of the fractions obtained by gel filtration showed that the 7-kDa band was immunoreactive with antibodies to PrP residues 90–102, 109–112, and 127–147 and was unreactive with antibodies to residues 58–71 and 151–165, suggesting that it corresponded to an internal fragment of the molecule (Fig. 2 C). Further purification of fraction 5 by HPLC on a reverse-phase C4 column yielded one major and several minor peaks (Fig. 2 D). Immunoblot analysis showed that the major peak (Fig. 2 D, peak 1) was immunoreactive with antibodies to PrP. Amino acid sequencing revealed that peak 1 was composed of a PrP fragment with a ragged N terminus, the major signals corresponding to residues 88 and 90. Peak 1 was digested with endoproteinase Lys-C; the enzymatic digest was fractionated by HPLC on a reverse-phase C18 column and the peptides subjected to microsequencing and laser desorption mass spectrometry. Only two cleavage sites (i.e. positions 106/107 and 110/111) resulting in three peptides were predicted on the basis of molecular weight, antigenic profile, N-terminal sequence analysis, and the known resistance to cleavage of Lys-Pro bonds at positions 101/102 and 104/105 of PrP. Microsequencing and mass spectrometry of the HPLC-purified peptides revealed a spectrum of N termini spanning residues 85–95, although Gly88, Gly90, and Gly92 were the predominant components (Fig.3, A and B). Moreover, the C terminus was heterogeneous corresponding to Arg148, Glu152, or Asn153 (Fig.3 C). Although the patient was heterozygous for the Ala → Val mutation at codon 117 and the Met/Val polymorphism at codon 129, only Val was found at these positions (Fig.4).Figure 4Amino acid sequence analysis of amyloid peptide. PrP peptides obtained by enzymatic digestion of the 7-kDa amyloid protein (peak 1 in Fig. 2 D) were subjected to automated microsequence analysis. A shows the HPLC analysis of PTH-derivatives released at cycles 6–8 during sequencing of this C-terminal portion of the amyloid protein. These cycles, equivalent to codons 116, 117, and 118, respectively, yielded Ala, Val, and Ala. B shows the HPLC analysis of PTH-derivatives released at cycles 18–20. These cycl
Referência(s)